<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03617328</url>
  </required_header>
  <id_info>
    <org_study_id>20085</org_study_id>
    <nct_id>NCT03617328</nct_id>
  </id_info>
  <brief_title>Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma</brief_title>
  <acronym>Mel-65</acronym>
  <official_title>Evaluation of Safety and Durable Immunogenicity of Melanoma Vaccination, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Craig L Slingluff, Jr</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celldex Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether it is safe to administer a peptide vaccine (6MHP) with adjuvants&#xD;
      and the CDX-1127 monoclonal antibody, and whether the adjuvants and the CDX-1127 monoclonal&#xD;
      antibody boost immune responses to the vaccine. In this study, the adjuvants are Montanide&#xD;
      ISA-51 and polyICLC. The investigators will monitor these effects by performing tests in the&#xD;
      laboratory on participants' blood and tissue from a vaccine site.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2018</start_date>
  <completion_date type="Anticipated">March 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 8, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of CDX-1127 administered with a melanoma vaccine</measure>
    <time_frame>30 days after receiving the last dose of study drug</time_frame>
    <description>Number of participants with dose-limiting toxicities based on CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity-Percent of patients with persistent CD4+ T cell responses to the 6MHP vaccine</measure>
    <time_frame>Day 127 or Day 176 or both</time_frame>
    <description>Number of participants with CD4+ T cell responses to 6 MHP persisting to day 127 or later.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunologic effect of CDX-1127 - Impact on regulatory T cells</measure>
    <time_frame>Day 22 and Day 85 (Note: Day 85 biopsy not required for participants whose Day 85 visit would be due after IRB approval of Protocol v12-03-2020)</time_frame>
    <description>Number of regulatory T cells per mm2 in the vaccine site microenvironment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic effect of CDX-1127 - Percent of circulating regulatory T cells</measure>
    <time_frame>through day 176</time_frame>
    <description>Percent of circulating regulatory T cells among CD4+ T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity - Frequency of circulating CD4+ Th1 responses</measure>
    <time_frame>through day 176</time_frame>
    <description>Number of participants with circulating CD4+ Th1 responses to vaccine antigens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity-Frequency of durable CD4+ Th1 memory responses</measure>
    <time_frame>Day 8 to Day 85</time_frame>
    <description>Number of participants with durable CD4+ Th1 memory response to vaccine antigens, measured as response at two or more consecutive time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity-Frequency of CD4+ Th1 memory responses</measure>
    <time_frame>Day 183</time_frame>
    <description>Number of participants with CD4+ Th1 memory response to vaccine antigens a week after the Day 176 booster vaccine.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Arm A: 6MHP/Montanide ISA-51 + polyICLC + CDX-1127</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mcg of 6MHP plus 0.9 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered subcutaneously on days 1, 8, 15, and 36. 200 mcg of 6MHP in Montanide ISA-51 adjuvant (without polyICLC) will be administered subcutaneously/intradermally on day 176. CDX-1127 (3mg/kg) will be administered intravenously on days 1, 36, and 78.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: 6MHP/Montanide ISA-51 + polyICLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mcg of 6MHP plus 0.9 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered subcutaneously on days 1, 8, 15, and 36. 200 mcg of 6MHP in Montanide ISA-51 adjuvant (without polyICLC) will be administered subcutaneously/intradermally on day 176.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>6MHP</intervention_name>
    <description>6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides</description>
    <arm_group_label>Arm A: 6MHP/Montanide ISA-51 + polyICLC + CDX-1127</arm_group_label>
    <arm_group_label>Arm B: 6MHP/Montanide ISA-51 + polyICLC</arm_group_label>
    <other_name>6 melanoma helper peptide vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montanide ISA-51</intervention_name>
    <description>Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant</description>
    <arm_group_label>Arm A: 6MHP/Montanide ISA-51 + polyICLC + CDX-1127</arm_group_label>
    <arm_group_label>Arm B: 6MHP/Montanide ISA-51 + polyICLC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>polyICLC</intervention_name>
    <description>polyICLC, local adjuvant</description>
    <arm_group_label>Arm A: 6MHP/Montanide ISA-51 + polyICLC + CDX-1127</arm_group_label>
    <arm_group_label>Arm B: 6MHP/Montanide ISA-51 + polyICLC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDX-1127</intervention_name>
    <description>CDX-1127, anti-CD27 monoclonal antibody</description>
    <arm_group_label>Arm A: 6MHP/Montanide ISA-51 + polyICLC + CDX-1127</arm_group_label>
    <other_name>Varlilumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Patients with stage IIB, IIC, III, or IV melanoma at original diagnosis or at&#xD;
             restaging after recurrence, rendered clinically free of disease by surgery, other&#xD;
             therapy, or spontaneous remission within 6 months prior to registration.&#xD;
&#xD;
          2. Patients with small radiologic or clinical findings of an indeterminate nature may be&#xD;
             eligible.&#xD;
&#xD;
          3. Patients with high-risk stage IIA melanoma (by DecisionDx Melanoma test, Castle&#xD;
             Biosciences, Inc., Friendswood, TX) may be eligible.&#xD;
&#xD;
          4. Participants may have had cutaneous, uveal, mucosal primary melanoma, or an unknown&#xD;
             primary melanoma. Diagnosis of melanoma must be confirmed by cytological or&#xD;
             histological examination. Staging of cutaneous melanoma will be based on version 8&#xD;
             AJCC staging system.&#xD;
&#xD;
          5. Participants who have had brain metastases will be eligible if all of the following&#xD;
             are true:&#xD;
&#xD;
               -  Each brain metastasis must have been completely removed by surgery or each&#xD;
                  unresected brain metastasis must have been treated with stereotactic&#xD;
                  radiosurgery.&#xD;
&#xD;
               -  No brain metastasis is &gt; 2 cm in diameter at the time of registration.&#xD;
&#xD;
               -  Any neurologic symptoms attributable to brain metastases have returned to&#xD;
                  baseline.There is no evidence of new or enlarging brain metastases.&#xD;
&#xD;
               -  The most recent surgical resections or gamma-knife therapy for malignant melanoma&#xD;
                  must have been completed ≥ 1 week and ≤ 6 months prior to registration.&#xD;
&#xD;
          6. ECOG performance status of 0 or 1.&#xD;
&#xD;
          7. Ability and willingness to give informed consent.&#xD;
&#xD;
          8. Adequate organ function&#xD;
&#xD;
          9. Age 18 years or older at registration.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          1. The following medications or treatments at any time within 4 weeks of registration:&#xD;
&#xD;
               -  Chemotherapy&#xD;
&#xD;
               -  Interferon (e.g. Intron-A®)&#xD;
&#xD;
               -  Radiation therapy (Stereotactic radiotherapy, such as gamma knife, can be used ≥&#xD;
                  1 week and ≤ 6 months prior to registration)&#xD;
&#xD;
               -  Allergy desensitization injections&#xD;
&#xD;
               -  High doses of systemic corticosteroids&#xD;
&#xD;
               -  Growth factors (e.g. Procrit®, Aranesp®, Neulasta®)&#xD;
&#xD;
               -  Interleukins (e.g. Proleukin®)&#xD;
&#xD;
               -  Any investigational medication&#xD;
&#xD;
               -  Targeted therapies specific for mutated BRAF or for MEK&#xD;
&#xD;
          2. Nitrosoureas within 6 weeks of registration.&#xD;
&#xD;
          3. Checkpoint molecule blockade therapy within 12 weeks of registration.&#xD;
&#xD;
          4. Known or suspected allergies to any component of the vaccine.&#xD;
&#xD;
          5. Previous vaccination with 6MHP.&#xD;
&#xD;
          6. Prior treatment with CDX-1127 or other CD27 agonistic antibody.&#xD;
&#xD;
          7. Pregnancy.&#xD;
&#xD;
          8. HIV positivity or evidence of active Hepatitis C virus.&#xD;
&#xD;
          9. Female participants must not be breastfeeding.&#xD;
&#xD;
         10. A medical contraindication or potential problem in complying with the requirements of&#xD;
             the protocol in the opinion of the investigator.&#xD;
&#xD;
         11. New York Heart Association classification as having Class III or IV heart disease.&#xD;
&#xD;
         12. Uncontrolled diabetes, defined as having an HgbA1c &gt; 8.5%.&#xD;
&#xD;
         13. Prior autoimmune disorders requiring cytotoxic or immunosuppressive therapy, or&#xD;
             autoimmune disorders with visceral involvement. Participants with an active autoimmune&#xD;
             disorder requiring these therapies are also excluded.&#xD;
&#xD;
         14. Participants with known addiction to alcohol or drugs who are actively taking those&#xD;
             agents, or participants with recent (within 1 year) or ongoing illicit IV drug use.&#xD;
&#xD;
         15. Participants who have received a live vaccine within 30 days of registration.&#xD;
&#xD;
         16. Body weight &lt; 110 pounds at registration, due to the amount and frequency with which&#xD;
             blood will be drawn.&#xD;
&#xD;
         17. Participants with prior autoimmune pneumonitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig L Slingluff, Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adela Mahmutovic, BA</last_name>
    <phone>434-982-6714</phone>
    <email>AM6BD@hscmail.mcc.virginia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adela Mahmutovic</last_name>
      <phone>434-982-6714</phone>
      <email>am6bd@hscmail.mcc.virginia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23284</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faith McFadden, RN, BSN</last_name>
      <phone>804-628-0616</phone>
      <email>mcfaddenfr@vcu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Carrie Donovan, RN</last_name>
      <phone>804-628-3836</phone>
      <email>donovan2@vcu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Poklepovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 28, 2018</study_first_submitted>
  <study_first_submitted_qc>July 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Craig L Slingluff, Jr</investigator_full_name>
    <investigator_title>Professor of Surgery; Director, Human Immune Therapy Center</investigator_title>
  </responsible_party>
  <keyword>peptide</keyword>
  <keyword>vaccine</keyword>
  <keyword>adjuvant</keyword>
  <keyword>6MHP</keyword>
  <keyword>polyICLC</keyword>
  <keyword>varlilumab</keyword>
  <keyword>CDX-1127</keyword>
  <keyword>Montanide ISA-51</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poly ICLC</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

